Biotinylated Human CLDN18.2 (N-6His, C-Avi)V2

产品介绍

{"gui_ge":"100ug","biao_da_su_zhu":"E.coli","biao_qian":"N-6His, C-AviV2","fen_zi_liang":"12.6 KDa","biao_guan_fen_zi_liang":"13 KDa, reducing conditions","xing_tai":"Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 8M Urea, 150mM NaCl, 5mM β-ME, pH 8.5.","chun_du":"Greater than 95% as determined by reducing SDS-PAGE.","nei_du_su_shui_ping":"Less than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.","chu_cun_fang_fa":"Store at ≤-70°C, stable for 6 months after receipt.\nStore at ≤-70°C, stable for 3 months under sterile conditions after opening. \nPlease minimize freeze-thaw cycles. ","yun_shu_tiao_jian":"The product is shipped on dry ice\/polar packs.\nUpon receipt, store it immediately at the temperature listed below.","bei_jing_shuo_ming":"Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG."}